28 completed, 22 unknown, 3 terminated, 2 recruiting. 25 Phase 1, 14 Phase 3, 5 Phase 4, 3 Not applicable, 1 Phase 2.
Follow IlDong Pharmaceutical Co Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects ID110521156, Placebo of 110521156 - Healthy Adult Subjects | Phase 1 | Recruiting | IlDong Pharmaceutical Co Ltd | 36 | 2024-11-13 | 2024-12-24 |
| Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects ID110521156, Placebo of ID110521156 - Healthy Adult Subjects | Phase 1 | Completed | IlDong Pharmaceutical Co Ltd | 36 | 2023-11-20 | 2024-11-25 |
| Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION) Clopidogrel treatment group, No antiplatelet or anticoagulant group - Coronary Artery Disease | Phase 4 | Recruiting | Seoul National University Hospital | 11086 | 2023-03-22 | 2025-12-31 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers ID120040002, Compound-X, Placebo comparator - Healthy | Phase 1 | Unknown | IlDong Pharmaceutical Co Ltd | 86 | 2022-12-07 | 2022-12-23 |
| Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects ID119031166M, Placebo - Healthy Participants | Phase 1 | Terminated | IlDong Pharmaceutical Co Ltd | 67 | 2022-10-10 | 2024-07-11 |
| To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers ID140009, ID1803+ID1805 - Dyslipidemias, Hypertension | Phase 1 | Unknown | IlDong Pharmaceutical Co Ltd | 60 | 2022-02-22 | 2022-02-28 |
| IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics [Part 1.1] IDG-16177, [Part 1.1] Placebo of IDG-16177, [Part 2] Sitagliptin - Type 2 Diabetes | Phase 1 | Unknown | IlDong Pharmaceutical Co Ltd | 94 | 2021-07-07 | 2022-08-11 |
| Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean Lasmiditan 50mg, Lasmiditan 100mg, Placebo - Acute Migraine | Phase 3 | Completed | IlDong Pharmaceutical Co Ltd | 294 | 2020-03-24 | 2021-04-01 |
| Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function Besifovir Dipivoxil Maleate - Renal Impairment | Phase 1 | Unknown | IlDong Pharmaceutical Co Ltd | 40 | 2020-02-13 | 2020-01-31 |
| To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults ID1803, ID1801, ID1803+ID1801 - Hypertension, Dyslipidemias | Phase 1 | Unknown | IlDong Pharmaceutical Co Ltd | 30 | 2020-02-01 | 2019-12-26 |
| Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers COL-144 50mg, COL-144 100mg, COL-144 200mg - Healthy | Phase 1 | Unknown | IlDong Pharmaceutical Co Ltd | 64 | 2019-08-01 | 2019-05-06 |
| Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate Besifovir Dipivoxil Maleate, Tenofovir disoproxil fumarate(TDF) - Hepatitis B, Besifovir Dipivoxil Maleate | Phase 4 | Unknown | IlDong Pharmaceutical Co Ltd | 152 | 2019-05-29 | 2019-12-17 |
| Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis RHT-3201 - Dermatitis, Atopic | Not applicable | Unknown | IlDong Pharmaceutical Co Ltd | 102 | 2019-03-15 | 2019-04-08 |
| A Food Effect Study of Besifovir in Healthy Subjects Besifovir dipivoxil - Food Effect, Health Subjects | Phase 4 | Completed | IlDong Pharmaceutical Co Ltd | 15 | 2019-01-13 | 2019-03-22 |
| Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Besifovir dipivoxil, L-carnitine, Tenofovir Alafenamide - Hepatitis B | Phase 4 | Unknown | IlDong Pharmaceutical Co Ltd | 76 | 2018-09-23 | 2018-08-23 |
| A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe NA (Observation study) - Mixed Dyslipidemia | Unknown | IlDong Pharmaceutical Co Ltd | 600 | 2018-09-01 | 2018-09-06 | |
| A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab. Hypertension, Dyslipidemia | Unknown | IlDong Pharmaceutical Co Ltd | 600 | 2018-09-01 | 2018-08-31 | |
| Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors NOV140101 (IDX-1197) - Advanced Solid Tumors | Phase 1 | Completed | Idience Co., Ltd. | 32 | 2017-08-29 | 2026-04-17 |
| A Post-marketing Surveillance to Assess Safety and Efficacy of Twotopsplus. Hypertension | Unknown | IlDong Pharmaceutical Co Ltd | 600 | 2017-07-25 | 2018-09-04 | |
| A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo Chronic Hepatitis b | Unknown | IlDong Pharmaceutical Co Ltd | 3000 | 2017-05-15 | 2018-08-31 |
Showing 20 of 55. Sign in to see all of them.
Hypertension (8) · Dyslipidemias (4) · Hepatitis B, Chronic (4) · Acute Coronary Syndrome (2) · Hepatitis B (2) · Hypercholesterolemia (2) · Neuralgia (2) · Prostatic Hyperplasia (2) · Alzheimer Disease (1) · Coronary Artery Disease (1) · Dermatitis, Atopic (1) · Diabetes Mellitus, Type 2 (1) · Erectile Dysfunction (1) · Esophageal Diseases (1) · Essential Hypertension (1)
Rosuvastatin Calcium (5) · Telmisartan (5) · Hydrochlorothiazide (4) · Tenofovir (3) · Valsartan (3) · ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (2) · APD791 (2) · Aspirin (2) · Carnitine (2) · Clopidogrel (2) · Ezetimibe (2) · Tamsulosin (2) · cilnidipine (2) · lasmiditan (2) · mosapride (2)
South Korea (37) · Germany (1) · United States (1)
Kyoung Sang You, MD, PhD (2) · Byung Seok Lee, M.D., Ph.D. (1) · Chun-ok Kim, MD (1) · Dong Ho Lee, MD, PhD (1) · Dong Joon Kim, M.D., Ph.D. (1) · Dong Ju Choi, M.D., Ph.D. (1) · Gyunseop Bae, M.D. (1) · Hong Soo Kim, M.D., Ph.D. (1) · Hyo-Soo Kim, MD, PhD (1) · Hyo-soo Kim, MD/PhD (1) · Hyung Joon Yim, M.D., Ph.D. (1) · Ildong Ildong (1) · Jae-Youn Cheong, M.D., Ph.D. (1) · Jeong-Ryeol Kim, Ph D. (1)
PMID 27432821, PMID 29248384, PMID 29402522, PMID 30448598, PMID 30904178, PMID 31564513, PMID 32297284, PMID 32355123, PMID 32811427, PMID 33493393, PMID 33795193, PMID 38473248, PMID 39945311